Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "dyspnea"

Posterior Mediastinal Mass

A 30-year-old man presented with chest pressure, shortness of breath, severe dyspnea on exertion, dysphagia, odynophagia, and a weight loss of 30 lb (14 kg) over a 2-month period. He had undergone orchiectomy 3 years earlier for stage 1 testicular ... New England Journal of Medicine, 18 hours ago
Pulmonary Embolism Consultant Live, 3 weeks ago

Dyspnea Index in Teens with Paradoxical Vocal Fold Motion

Reuters Health Information By Will Boggs MD August18,2014 NEW YORK (Reuters Health) - The Dyspnea Index (DI) reliably assesses quality of life in adolescents with exercise-induced paradoxical vocal fold motion (PVFM), according to a new study. ...
 General Medicine eJournal3 days ago

Case 9-2014: A Woman with Increasing Dyspnea

New England Journal of Medicine, Volume 371, Issue 4, Page 387-389,
 New England Journal of Medicine4 weeks ago Case 22-2014  New England Journal of Medicine1 month ago Case 22-2014 — A 40-Year-Old Woman with Postpartum Dyspnea and Hypoxemia  New England Journal of Medicine1 month ago A Woman with Postpartum Dyspnea and Hypoxemia  New England Journal of Medicine1 month ago

Why Does COPD Cause Weight Loss?

Living with chronic obstructive pulmonary disease (COPD) means finding ways to breathe easier, but shortness of breath dyspnea doesn't only affect your lungs.Shortness of breath can also make it difficult to eat, leading to another common ...
 BlackDoctor.org1 month ago Factors predictive of airflow obstruction among Veterans with presumed empiric diagnosis and treatment of COPD  CHEST3 weeks ago

Amyotrophic Lateral Sclerosis Presenting Respiratory Failure as the Sole Initial Manifestation

References Miller RD, Mulder DW, Fowler WS, Olsen AM: Exertional dyspnea: a primary complaint in unusual cases of progressive muscular atrophy and amyotrophic lateral sclerosis. Ann Intern Med 1957;46:119-125. Fromm GB, Wisdom ...
 Sexual Development1 week ago
Consultant Live

Rash in an Immunocompromised Man: Your Dx?

A 78-year-old man had a rash for 5 days and dyspnea for 2-weeks; he also had a cough with white sputum and occasional fever without chills. He had hypertension, T2 diabetes, and mantle cell lymphoma after splenectomy. He started taking vancomycin ...
 Consultant Live3 weeks ago
SPi World News

Sucampo Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone

BETHESDA, Md., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) ( Nasdaq:SCMP ), a global biopharmaceutical company, today announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply ...
 Crawford Financial Planning6 hours ago SUCAMPO PHARMACEUTICALS : Announces New Exclusive Global Manufacturing and Supply Agreement for Lubiprostone  4 Traders5 hours ago Eisai Inc. And Arena Pharmaceuticals, Inc. Announce Publication Of Post-Hoc Analyses Of Lorcaserin Phase 3 Clinical Trial Results In Obesity  BioSpace3 weeks ago Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity  TickerTech.com3 weeks ago
[x]  

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

Related Stocks SNI - Scripps Networks Interactive Inc Sym Last Chg Pct Volume SNI81.71+0.21+0.26%438,653OGXI3.11-0.10-3.12%85,338TEVA53.63+0.64+1.21%2,053,454 BOTHELL, Wash. and VANCOUVER, British Columbia , Aug. 21, 2014 /PRNewswire/ -- OncoGenex ...
 Barchart6 hours ago TEVA PHARMACEUTICAL : OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer  4 Traders6 hours ago
[x]  

Long-Acting Version Of Baxter International, Inc.'s Hemophilia A Drug BAX 855 Succeeds In Study

Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients * Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared ...
 BioSpace10 hours ago Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients  TVNewsCheck13 hours ago Nektar Therapeutics : Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients  4 Traders6 hours ago BAXTER : Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients  4 Traders13 hours ago
[x]  

New Amsterdam Sciences Continues Pact With Dr. Jacob Finkelstein, PhD to Advance Pulmonary Fibrosis Research

SCOTTSDALE, AZ -- (Marketwired) -- 08/21/14 -- New Amsterdam Sciences (NAS), an emerging bioscience company, announced today that while advancing to phase1 clinical trials it will continue its commitment for further research with renowned ...
 Vision Monday15 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less